Yei-won Lee

Learn More
OBJECTIVE To assess the safety, tolerability, and preliminary efficacy of NP001, a novel immune regulator of inflammatory monocytes/macrophages, for slowing progression of amyotrophic lateral sclerosis (ALS). METHODS This was a phase 2 randomized, double-blind, placebo-controlled trial of NP001 in 136 patients with ALS of <3 years' duration and forced(More)
INTRODUCTION PLS is defined as pure upper motor neuron disease/dysfunction (PUMND) beyond 48 months after symptom onset. We know little about its early stages, but such knowledge would help to identify the mechanisms underlying PLS and ALS and determine why PLS patients seem to be protected against lower MND (LMND). METHODS We reviewed 622 MND cases(More)
Methods M.E.A.D. was used as a measurement tool. Thirty healthy volunteers from the University were recruited. We measured once every week and twice every time in a 30 minute interval. In the first week, 30 subjects sat and rested during the interval, which served as the control group. We compared these two measurements in the first week by reliability(More)
  • 1